Brief: Akari Therapeutics Granted FDA Rare Pediatric Disease Designation Of Nomacopan
10/11/2022 13:22
Nov 10 (Reuters) - Akari Therapeutics PLC AKTX.O :
* AKARI THERAPEUTICS GRANTED FDA RARE PEDIATRIC DISEASE
DESIGNATION OF NOMACOPAN FOR THE TREATMENT OF PEDIATRIC HSCT-TMA
Source text for Eikon: ID:nGNE7rHxQl
Further company coverage: AKTX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Akari Therapeutics
See all newsBrief: Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity In Urothelial Cancer Preclinical Models
UK's Akari Therapeutics Q2 net loss widens on higher R&D for AKTX-101
Akari Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Akari Therapeutics PLC expected to post a loss of $1.40 a share - Earnings Preview
Brief: Akari Therapeutics Enters Strategic Research Collaboration With Whitehawk Therapeutics